cat no | io1067, io1068

ioGlutamatergic Neurons APP V717I/WT^™

Human iPSC-derived Alzheimer's disease model

ioGlutamatergic Neurons APP V717I/WT are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous V717I mutation in the APP gene encoding amyloid precursor protein. These cells offer a rapidly maturing, disease relevant system for investigating the role of the APP London mutation in early-onset Alzheimer's disease (AD).

Place your order

Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.

Vial size

Quantity

Price

per vial

Add to basket

Request a quote Chat with us

Benchtop benefits

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the APP missense mutation on early-onset AD.

Scalable

With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Highly characterised and defined

ioGlutamatergic Neurons APP V717I/WT express neuron-specific markers comparably to the wild type control

Homogenous expression of MAP2 and TUBB3

io1067-io1068-ioGlutamatergic Neurons APP-V717I-het-ICC-MAP2-TUBB3

Homogenous expression of VGLUT2

io1067-io1068-ioGlutamatergic Neurons APP-V717I-het-ICC-MAP2-VGLUT2

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (left tab) and glutamatergic neuron-specific transporter VGLUT2 (right tab) in ioGlutamatergic Neurons APP V717I/WT clones compared to the genetically matched control. 100X magnification.

ioGlutamatergic Neurons APP V717I/WT form structural neuronal networks by day 11

ioGlutamatergic Neurons APP V717I/WT morphology from day1 to 11 post-thaw.

ioGlutamatergic Neurons APP V717I/WT clones mature rapidly and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.

ioGlutamatergic Neurons APP V717I/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming

Gene expression analysis demonstrates that ioGlutamatergic Neurons APP V717I/WT clones and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Disease-related APP is expressed in ioGlutamatergic Neurons APP V717I/WT following reprogramming

CL35 (io1067)

CL58 (io1068)

RT-qPCR analysis demonstrates a similar expression level of the APP gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons APP V717I/WT clones at day 11 post-revival. Data normalised to HMBS, n=2 replicates.

Cells arrive ready to plate

ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons APP V717I/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Industry leading seeding density

ioGlutamatergic_Neurons_seeding_density_small_96_384

The recommended minimum seeding density is 30,000 cells/cm², compared to up to 250,000 cells/cm² for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

30,000 cells/cm²

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Heterozygous V717I missense mutation in the APP gene

Applications

Alzheimer's disease research
Drug discovery and development
Disease modelling

Available clones

io1067 | APP V717I/WT (CL35)
io1068 | APP V717I/WT (CL58)

Product use

ioCells are for research use only

Supporting documentation

User Manual

Limited Use License & Statement of Use

Product resources

Poster

Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease

Smith et al.
bit.bio
2024

Downlaod

User manual

ioGlutamatergic Neurons Wild Type and related disease models | User Manual

bit.bio

2024

Download

Case study

Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons™

Professor Deepak Srivastava

Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders

King’s College London

Download

Webinar

Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now

Publication

3D bioprinting of iPSC neuron-astrocyte coculture

Whitehouse, et al
JoVE Journal of Visualized Experiments
2023

Using ioGlutamatergic Neurons

Webinar

Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now

Talk

Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency

Innovation showcase talk at ISSCR

Marius Wernig MD, PhD | Stanford

Mark Kotter, MD, PhD | bit.bio

Watch now

Poster

Modelling neurodegeneration: Human isogenic system to study FTD & ALS

Oosterveen, et al

bit.bio & Charles River Laboratories

2023

Download

Webinar

Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University

Watch now

Talk

Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models

Madeleine Garrett | Field Application Specialist | bit.bio

Watch now

Poster

Development and characterisation of a robust in vitro disease model to study tauopathies

Ritsma et al

Charles River Laboratories & bit.bio

2022

Download

Poster

Validation of ALS-relevant phenotypes in precision reprogrammed iPSC-derived glutamatergic Neurons containing a TDP-43 M337V mutation.

Ritsma, et al

Charles River Laboratories & bit.bio

2022

Download

Poster

Rapid and consistent generation of functional microglia from reprogrammed hiPSCs to study neurodegeneration and neuroinflammation

Raman, et al

bit.bio

2022

Download

Application note

Developing next-generation in vitro phenotypic assays for Huntington’s disease by combining a precision reprogrammed hiPSC-derived disease model with high-density microelectrode arrays

bit.bio | MaxWell Biosystems | Charles River Laboratories

2022

Download